These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15230364)

  • 1. An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.
    Reeves P; Cooke J; Lloyd A; Hutchings A
    Pharm World Sci; 2004 Jun; 26(3):160-8. PubMed ID: 15230364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Offord R; Lloyd AC; Anderson P; Bearne A
    Pharm World Sci; 2004 Aug; 26(4):214-20. PubMed ID: 15446778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
    Dunn CJ; Goa KL
    Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
    Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
    Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
    Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
    J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
    Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
    Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
    Gómez-Outes A; Rocha E; Martínez-González J; Kakkar VV
    Pharmacoeconomics; 2006; 24(1):81-92. PubMed ID: 16445305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
    Argenta C; Ferreira MA; Sander GB; Moreira LB
    Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin.
    Jones TE; Smith BJ; Polasek JF
    Expert Opin Pharmacother; 2004 Sep; 5(9):1887-97. PubMed ID: 15330727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Deitelzweig SB; Becker R; Lin J; Benner J
    Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD; Goeree R; Crowther MA; O'Brien BJ
    Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.
    Heaton D; Pearce M
    Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
    Etchells E; McLeod RS; Geerts W; Barton P; Detsky AS
    Arch Intern Med; 1999 Jun; 159(11):1221-8. PubMed ID: 10371230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome.
    Rosenthal N; Xiao Z; Kartashov A; Levorsen A; Shah BR
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):93-101. PubMed ID: 32578166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospital-based costs associated with venous thromboembolism treatment regimens.
    Merli G; Ferrufino C; Lin J; Hussein M; Battleman D
    J Thromb Haemost; 2008 Jul; 6(7):1077-86. PubMed ID: 18445118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.